Diet, gut microbes, and the pathogenesis of inflammatory bowel diseases

Molecular Nutrition and Food Research

Volumn 61, Issue 1, 2017, Pages

  Dolan, Kyle T ^a   Chang, Eugene B ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Diet; IBD; Microbial metabolism; Microbiota; Pathogenesis

Indexed keywords

DIET; DIET THERAPY; GASTROENTERITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTESTINE; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

DIET; GASTROENTERITIS; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; RISK FACTORS;

EID: 84994666611     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201600129     Document Type: Review

References (141)

1. Molodecky, N.A., Soon, I. S., Rabi, D. M., Ghali, W. A. et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46–54.
2. Prideaux, L., Kamm, M. A., De Cruz, P. P., Chan, F. K. L. et al., Inflammatory bowel disease in Asia: a systematic review. J. Gastroenterol. Hepatol. 2012, 27, 1266–1280.
3. Barreiro-de Acosta, M., Alvarez Castro, A., Souto, R., Iglesias, M. et al., Emigration to western industrialized countries: a risk factor for developing inflammatory bowel disease. J. Crohns. Colitis 2011, 5, 566–569.
4. Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H. et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119–124.
5. Huang, C., Haritunians, T., Okou, D. T., Cutler, D. J. et al., Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans. Gastroenterology 2015, 149, 1575–1586.
6. Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C. et al., Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 2015, 47, 979–986.
7. Ananthakrishnan, A. N., Epidemiology and risk factors for IBD. Nat. Rev. Gastroenterol. Hepatol. 2015, 12, 205–217.
8. Kostic, A. D., Xavier, R. J., Gevers, D., The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014, 146, 1489–1499.
9. Gentschew, L., Ferguson, L. R., Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol. Nutr. Food Res. 2012, 56, 524–535.
10. Leone, V. A., Cham, C. M., Chang, E. B., Diet, gut microbes, and genetics in immune function: can we leverage our current knowledge to achieve better outcomes in inflammatory bowel diseases? Curr. Opin. Immunol. 2014, 31, 16–23.
11. Lee, D., Albenberg, L., Compher, C., Baldassano, R. et al., Diet in the pathogenesis and treatment of inflammatory bowel diseases. Gastroenterology 2015, 148, 1087–1106.
12. Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E. et al., The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 2009, 1, 6ra14.
13. Nyangale, E. P., Mottram, D. S., Gibson, G. R., Gut microbial activity, implications for health and disease: the potential role of metabolite analysis. J. Proteome Res. 2012, 11, 5573–5585.
14. Chapman-Kiddell, C. A., Davies, P. S. W., Gillen, L., Radford-Smith, G. L., Role of diet in the development of inflammatory bowel disease. Inflamm. Bowel Dis. 2010, 16, 137–151.
15. Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K. et al., Linking long-term dietary patterns with gut microbial enterotypes. Science 2011, 334, 105–108.
16. Hou, J. K., Abraham, B., El-Serag, H., Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am. J. Gastroenterol. 2011, 106, 563–573.
17. Jantchou, P., Morois, S., Clavel-Chapelon, F., Boutron-Ruault, M.-C. et al., Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study. Am. J. Gastroenterol. 2010, 105, 2195–2201.
18. Richman, E., Rhodes, J. M., Review article: evidence-based dietary advice for patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 2013, 38, 1156–1171.
19. Ananthakrishnan, A. N., Khalili, H., Konijeti, G. G., Higuchi, L. M. et al., Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut 2014, 63, 776–784.
20. Racine, A., Carbonnel, F., Chan, S. S. M., Hart, A. R. et al., Dietary patterns and risk of inflammatory bowel disease in Europe. Inflamm. Bowel Dis. 2016, 22, 345–354.
21. Chan, S. S. M., Luben, R., van Schaik, F., Oldenburg, B. et al., Carbohydrate intake in the etiology of Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 2014, 20, 2013–2021.
22. Sakamoto, N., Kono, S., Wakai, K., Fukuda, Y. et al., Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm. Bowel Dis. 2005, 11, 154–163.
23. Amre, D. K., D'Souza, S., Morgan, K., Seidman, G. et al., Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am. J. Gastroenterol. 2007, 102, 2016–2025.
24. Hart, A. R., Luben, R., Olsen, A., Tjonneland, A. et al., Diet in the aetiology of ulcerative colitis: a European prospective cohort study. Digestion 2008, 77, 57–64.
25. Chan, S. S. M., Luben, R., Olsen, A., Tjonneland, A. et al., Association between high dietary intake of the n-3 polyunsaturated fatty acid docosahexaenoic acid and reduced risk of Crohn's disease. Aliment. Pharmacol. Ther. 2014, 39, 834–842.
26. John, S., Luben, R., Shrestha, S. S., Welch, A. et al., Dietary n-3 polyunsaturated fatty acids and the aetiology of ulcerative colitis: a UK prospective cohort study. Eur. J. Gastroenterol. Hepatol. 2010, 22, 602–606.
27. Tjonneland, A., Overvad, K., Bergmann, M. M., Nagel, G. et al., Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 2009, 58, 1606–1611.
28. Costea, I., Mack, D. R., Lemaitre, R. N., Israel, D. et al., Interactions between the dietary polyunsaturated fatty acid ratio and genetic factors determine susceptibility to pediatric Crohn's disease. Gastroenterology 2014, 146, 929–931.
29. D'Souza, S., Levy, E., Mack, D., Israel, D. et al., Dietary patterns and risk for Crohn's disease in children. Inflamm. Bowel Dis. 2008, 14, 367–373.
30. Ananthakrishnan, A. N., Khalili, H., Konijeti, G. G., Higuchi, L. M. et al., A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology 2013, 145, 970–977.
31. Van der Logt, E. M. J., Blokzijl, T., Van der Meer, R., Faber, K. N. et al., Westernized high-fat diet accelerates weight loss in dextran sulfate sodium-induced colitis in mice, which is further aggravated by supplementation of heme. J. Nutr. Biochem. 2013, 24, 1159–1165.
32. Devkota, S., Wang, Y., Musch, M. W., Leone, V. et al., Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012, 487, 104–108.
33. Whiting, C. V, Bland, P. W., Tarlton, J. F., Dietary n-3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis. Inflamm. Bowel Dis. 2005, 11, 340–349.
34. Mbodji, K., Charpentier, C., Guérin, C., Querec, C. et al., Adjunct therapy of n-3 fatty acids to 5-ASA ameliorates inflammatory score and decreases NF-κB in rats with TNBS-induced colitis. J. Nutr. Biochem. 2013, 24, 700–705.
35. Matsunaga, H., Hokari, R., Kurihara, C., Okada, Y. et al., Omega-3 fatty acids exacerbate DSS-induced colitis through decreased adiponectin in colonic subepithelial myofibroblasts. Inflamm. Bowel Dis. 2008, 14, 1348–1357.
36. Roberts, C. L., Keita, A. V, Duncan, S. H., O'Kennedy, N. et al., Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010, 59, 1331–1339.
37. Chassaing, B., Koren, O., Goodrich, J. K., Poole, A. C. et al., Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 2015, 519, 92–96.
38. Roberts, C. L., Rushworth, S. L., Richman, E., Rhodes, J. M., Hypothesis: increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. J. Crohns. Colitis 2013, 7, 338–341.
39. Bäckhed, F., Ley, R. E., Sonnenburg, J. L., Peterson, D. A. et al., Host-bacterial mutualism in the human intestine. Science 2005, 307, 1915–1920.
40. Hugot, J. P., Chamaillard, M., Zouali, H., Lesage, S. et al., Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411, 599–603.
41. Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L. et al., A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411, 603–606.
42. Ott, S. J., Musfeldt, M., Wenderoth, D. F., Hampe, J. et al., Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut 2004, 53, 685–693.
43. Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K. et al., Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006, 55, 205–211.
44. Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D. et al., Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012, 13, R79.
45. Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y. et al., The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe 2014, 15, 382–392.
46. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O. et al., Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 16731–16736.
47. Darfeuille-Michaud, A., Boudeau, J., Bulois, P., Neut, C. et al., High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127, 412–421.
48. Ohkusa, T., Sato, N., Ogihara, T., Morita, K. et al., Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J. Gastroenterol. Hepatol. 2002, 17, 849–853.
49. Consortium, T.H.M.P., A framework for human microbiome research. Nature 2012, 486, 215–221.
50. Li, J., Jia, H., Cai, X., Zhong, H. et al., An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 2014, 32, 834–841.
51. Chow, J., Tang, H., Mazmanian, S. K., Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr. Opin. Immunol. 2011, 23, 473–480.
52. Gensollen, T., Iyer, S. S., Kasper, D. L., Blumberg, R. S., How colonization by microbiota in early life shapes the immune system. Science (80-.). 2016, 352, 539–544.
53. Ng, S. C., Tang, W., Leong, R. W., Chen, M. et al., Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut 2015, 64, 1063–1071.
54. Timm, S., Svanes, C., Janson, C., Sigsgaard, T. et al., Place of upbringing in early childhood as related to inflammatory bowel diseases in adulthood: a population-based cohort study in Northern Europe. Eur. J. Epidemiol. 2014, 29, 429–437.
55. Hennet, T., Borsig, L., Breastfed at Tiffany's. Trends Biochem. Sci. 2016, 41, 508–518.
56. Rogier, E. W., Frantz, A. L., Bruno, M. E. C., Wedlund, L. et al., Secretory antibodies in breast milk promote long-term intestinal homeostasis by regulating the gut microbiota and host gene expression. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 3074–3079.
57. Klement, E., Cohen, R. V, Boxman, J., Joseph, A. et al., Breastfeeding and risk of inflammatory bowel disease: a systematic review with meta-analysis. Am. J. Clin. Nutr. 2004, 80, 1342–1352.
58. Barclay, A. R., Russell, R. K., Wilson, M. L., Gilmour, W. H. et al., Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J. Pediatr. 2009, 155, 421–426.
59. Khalili, H., Ananthakrishnan, A. N., Higuchi, L. M., Richter, J. M. et al., Early life factors and risk of inflammatory bowel disease in adulthood. Inflamm. Bowel Dis. 2013, 19, 542–547.
60. De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M. et al., Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 14691–14696.
61. David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B. et al., Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505, 559–563.
62. Baumgart, M., Dogan, B., Rishniw, M., Weitzman, G. et al., Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 2007, 1, 403–418.
63. Macfarlane, S., Macfarlane, G. T., Regulation of short-chain fatty acid production. Proc. Nutr. Soc. 2003, 62, 67–72.
64. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. et al., Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504, 446–450.
65. Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M. et al., The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science (80-.). 2013, 341, 569–574.
66. Maslowski, K. M., Vieira, A. T., Ng, A., Kranich, J. et al., Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461, 1282–1286.
67. Treem, W. R., Ahsan, N., Shoup, M., Hyams, J. S., Fecal short-chain fatty acids in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 1994, 18, 159–164.
68. Atarashi, K., Tanoue, T., Oshima, K., Suda, W. et al., Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013, 500, 232–236.
69. Martín, R., Chain, F., Miquel, S., Lu, J. et al., The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm. Bowel Dis. 2014, 20, 417–430.
70. Qiu, X., Zhang, M., Yang, X., Hong, N. et al., Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. J. Crohns Colitis 2013, 7, e558–e568.
71. Silveira, A. L. M., Ferreira, A. V. M., de Oliveira, M. C., Rachid, M. A. et al., Preventive rather than therapeutic treatment with high fiber diet attenuates clinical and inflammatory markers of acute and chronic DSS-induced colitis in mice. Eur. J. Nutr. 2015, doi: 10.1007/s00394-015-1068-x.
72. Wedlake, L., Slack, N., Andreyev, H. J. N., Whelan, K., Fiber in the treatment and maintenance of inflammatory bowel disease: a systematic review of randomized controlled trials. Inflamm. Bowel Dis. 2014, 20, 576–586.
73. Joyce, S. A., Gahan, C. G. M., Bile acid modifications at the microbe-host interface: potential for nutraceutical and pharmaceutical interventions in host health. Annu. Rev. Food Sci. Technol. 2016, doi: 10.1146/annurev-food-041715-033159.
74. Islam, K.B.M.S., Fukiya, S., Hagio, M., Fujii, N. et al., Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011, 141, 1773–1781.
75. Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L. et al., Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60, 463–472.
76. Duboc, H., Rajca, S., Rainteau, D., Benarous, D. et al., Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013, 62, 531–539.
77. Ogilvie, L. A., Jones, B. V, Dysbiosis modulates capacity for bile acid modification in the gut microbiomes of patients with inflammatory bowel disease: a mechanism and marker of disease? Gut 2012, 61, 1642–1643.
78. Carbonero, F., Benefiel, A. C., Alizadeh-Ghamsari, A. H., Gaskins, H. R., Microbial pathways in colonic sulfur metabolism and links with health and disease. Front. Physiol. 2012, 3, 448.
79. Wallace, J. L., Blackler, R. W., Chan, M. V, Da Silva, G. J. et al., Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid. Redox Signal. 2015, 22, 398–410.
80. Gibson, G. R., Cummings, J. H., Macfarlane, G. T., Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 1991, 9, 103–111.
81. Levine, J., Ellis, C. J., Furne, J. K., Springfield, J. et al., Fecal hydrogen sulfide production in ulcerative colitis. Am. J. Gastroenterol. 1998, 93, 83–87.
82. Babidge, W., Millard, S., Roediger, W., Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: implications for ulcerative colitis. Mol. Cell. Biochem. 1998, 181, 117–124.
83. Miller, T. W., Wang, E. A., Gould, S., Stein, E. V et al., Hydrogen sulfide is an endogenous potentiator of T cell activation. J. Biol. Chem. 2012, 287, 4211–4221.
84. Attene-Ramos, M. S., Wagner, E. D., Plewa, M. J., Gaskins, H. R., Evidence that hydrogen sulfide is a genotoxic agent. Mol. Cancer Res. 2006, 4, 9–14.
85. Wallace, J. L., Vong, L., McKnight, W., Dicay, M. et al., Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 2009, 137, 569–578, 578.e1.
86. Fasolino, I., Izzo, A. A., Clavel, T., Romano, B. et al., Orally administered allyl sulfides from garlic ameliorate murine colitis. Mol. Nutr. Food Res. 2015, 59, 434–42.
87. Motta, J.-P., Flannigan, K. L., Agbor, T. A., Beatty, J. K. et al., Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm. Bowel Dis. 2015, 21, 1006–1017.
88. Laue, H., Denger, K., Cook, A. M., Taurine reduction in anaerobic respiration of Bilophila wadsworthia RZATAU. Appl. Environ. Microbiol. 1997, 63, 2016–2021.
89. Fukamachi, H., Nakano, Y., Yoshimura, M., Koga, T., Cloning and characterization of the L-cysteine desulfhydrase gene of Fusobacterium nucleatum. FEMS Microbiol. Lett. 2002, 215, 75–80.
90. Strauss, J., Kaplan, G. G., Beck, P. L., Rioux, K. et al., Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm. Bowel Dis. 2011, 17, 1971–1978.
91. Monteleone, I., Rizzo, A., Sarra, M., Sica, G. et al., Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology 2011, 141, 237–248.
92. Zhao, Y., Ma, T., Chen, W., Chen, Y. et al., MicroRNA-124 promotes the intestinal inflammation by targeting AHR in Crohn's disease. J. Crohns. Colitis 2016, doi: 10.1093/ecco-jcc/jjw010.
93. Monteleone, I., Zorzi, F., Marafini, I., Fusco, D. Di et al., Aryl hydrocarbon receptor-driven signals inhibit collagen synthesis in the gut. Eur. J. Immunol. 2016, doi: 10.1002/eji.201445228.
94. Li, Y., Innocentin, S., Withers, D. R., Roberts, N. A. et al., Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 2011, 147, 629–640.
95. Monteleone, I., MacDonald, T. T., Pallone, F., Monteleone, G., The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr. Opin. Gastroenterol. 2012, 28, 310–313.
96. Zelante, T., Iannitti, R., Cunha, C., DeLuca, A. et al., Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013, 39, 372–385.
97. Lamas, B., Richard, M. L., Leducq, V., Pham, H.-P. et al., CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med. 2016, 22, 598–605.
98. Serban, D. E., Microbiota in inflammatory bowel disease pathogenesis and therapy: is it all about diet? Nutr. Clin. Pract. 2015, 30, 760–779.
99. Hansen, J. J., Sartor, R. B., Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr. Treat. Options Gastroenterol. 2015, 13, 105–120.
100. Feagan, B. G., Sandborn, W. J., Mittmann, U., Bar-Meir, S. et al., Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008, 299, 1690–1697.
101. Lev-Tzion, R., Griffiths, A. M., Leder, O., Turner, D., Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2014, 2, CD006320.
102. D'Haens, G. R., Sartor, R. B., Silverberg, M. S., Petersson, J. et al., Future directions in inflammatory bowel disease management. J. Crohns. Colitis 2014, 8, 726–734.
103. Shah, S. C., Colombel, J.-F., Sands, B. E., Narula, N., Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2016, doi: 10.1016/j.cgh.2016.01.015.
104. Shah, S. C., Colombel, J.-F., Sands, B. E., Narula, N., Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment. Pharmacol. Ther. 2016, 43, 317–333.
105. Mooiweer, E., Severs, M., Schipper, M. E. I., Fidder, H. H. et al., Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J. Crohns. Colitis 2015, 9, 50–55.
106. Solem, C. A., Loftus, E. V, Tremaine, W. J., Harmsen, W. S. et al., Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis. 2005, 11, 707–712.
107. Henriksen, M., Jahnsen, J., Lygren, I., Stray, N. et al., C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57, 1518–1523.
108. Zachos, M., Tondeur, M., Griffiths, A. M., Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2007, 1, CD000542.
109. Grover, Z., Muir, R., Lewindon, P., Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J. Gastroenterol. 2014, 49, 638–645.
110. Grover, Z., Burgess, C., Muir, R., Reilly, C. et al., Early mucosal healing with exclusive enteral nutrition is associated with improved outcomes in newly diagnosed children with luminal Crohn's disease. J. Crohns. Colitis 2016, doi: 10.1093/ecco-jcc-/jjw075.
111. Sigall-Boneh, R., Pfeffer-Gik, T., Segal, I., Zangen, T. et al., Partial enteral nutrition with a Crohn's disease exclusion diet is effective for induction of remission in children and young adults with Crohn's disease. Inflamm. Bowel Dis. 2014, 20, 1353–1360.
112. Chiba, M., Abe, T., Tsuda, H., Sugawara, T. et al., Lifestyle-related disease in Crohn's disease: relapse prevention by a semi-vegetarian diet. World J. Gastroenterol. 2010, 16, 2484–2495.
113. Prince, A. C., Myers, C. E., Joyce, T., Irving, P. et al., Fermentable carbohydrate restriction (Low FODMAP Diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2016, 22, 1129–1136.
114. Maagaard, L., Ankersen, D. V, Végh, Z., Burisch, J. et al., Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World J. Gastroenterol. 2016, 22, 4009–4019.
115. van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S. et al., Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013, 368, 407–415.
116. Anderson, J. L., Edney, R. J., Whelan, K., Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012, 36, 503–516.
117. Kump, P. K., Gröchenig, H.-P., Lackner, S., Trajanoski, S. et al., Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm. Bowel Dis. 2013, 19, 2155–2165.
118. Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J. et al., Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015, 149, 102–109.
119. Shen, J., Zuo, Z.-X., Mao, A.-P., Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm. Bowel Dis. 2014, 20, 21–35.
120. Mardini, H. E., Grigorian, A. Y., Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis. Inflamm. Bowel Dis. 2014, 20, 1562–1567.
121. Miele, E., Pascarella, F., Giannetti, E., Quaglietta, L. et al., Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 2009, 104, 437–443.
122. Sood, A., Midha, V., Makharia, G. K., Ahuja, V. et al., The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 2009, 7, 1202–1209.
123. Tursi, A., Brandimarte, G., Papa, A., Giglio, A. et al., Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 2010, 105, 2218–2227.
124. Henker, J., Müller, S., Laass, M. W., Schreiner, A. et al., Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. Zeitschrift Für Gastroenterol. 2008, 46, 874–875.
125. Petersen, A. M., Mirsepasi, H., Halkjær, S. I., Mortensen, E. M. et al., Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. J. Crohns. Colitis 2014, 8, 1498–1505.
126. Fedorak, R. N., Feagan, B. G., Hotte, N., Leddin, D. et al., The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin. Gastroenterol. Hepatol. 2015, 13, 928–935.
127. Kanauchi, O., Suga, T., Tochihara, M., Hibi, T. et al., Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J. Gastroenterol. 2013, 37, 67–72.
128. Ben-Arye, E., Goldin, E., Wengrower, D., Stamper, A. et al., Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand. J. Gastroenterol. 2002, 37, 444–449.
129. Benjamin, J. L., Hedin, C. R. H., Koutsoumpas, A., Ng, S. C. et al., Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011, 60, 923–929.
130. Steed, H., Macfarlane, G. T., Blackett, K. L., Bahrami, B. et al., Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn's disease. Aliment. Pharmacol. Ther. 2010, 32, 872–883.
131. Fukumoto, S., Toshimitsu, T., Matsuoka, S., Maruyama, A. et al., Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. Immunol. Cell Biol. 2014, 92, 460–465.
132. Candela, M., Perna, F., Carnevali, P., Vitali, B. et al., Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: Adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int. J. Food Microbiol. 2008, 125, 286–292.
133. Fukuda, S., Toh, H., Hase, K., Oshima, K. et al., Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011, 469, 543–547.
134. Colombel, J. F., Rutgeerts, P., Reinisch, W., Esser, D. et al., Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141, 1194–1201.
135. Baert, F., Moortgat, L., Van Assche, G., Caenepeel, P. et al., Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138, 463–468.
136. Borrelli, O., Cordischi, L., Cirulli, M., Paganelli, M. et al., Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 2006, 4, 744–753.
137. Momozawa, Y., Deffontaine, V., Louis, E., Medrano, J. F., Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. PLoS One 2011, 6, e16952.
138. Belkaid, Y., Naik, S., Compartmentalized and systemic control of tissue immunity by commensals. Nat. Immunol. 2013, 14, 646–53.
139. Faith, J. J., Colombel, J.-F., Gordon, J. I., Identifying strains that contribute to complex diseases through the study of microbial inheritance. Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 633–640.
140. Miquel, S., Leclerc, M., Martin, R., Chain, F. et al., Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. MBio 2015, 6, e00300–15.
141. Jansson, J., Willing, B., Lucio, M., Fekete, A. et al., Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One 2009, 4, e6386.